The prognostic value of selected indices combination in hepatocellular carcinoma patients treated with sorafenib
Reports of Practical Oncology and Radiotherapy · 27.02.2026 · 31 (1) · 59-67
DOI: 10.5603/rpor.111180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reports of Practical Oncology and Radiotherapy, online erschienen am 27.02.2026. Verfasst von Radosław Osmański und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Immuno-Oncology, Greater Poland Cancer Centre, Poznan, Poland. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology and Immuno-Oncology, Greater Poland Cancer Centre, Poznan, Poland.
- Department of Gynecological Oncology, Poznan University of Medical Sciences, Poznan, Poland.
- Department of Pathology and Cancer Prevention, Poznan University of Medical Sciences, Poznan, Poland.
- Department of Medical Education and Communication, Poznan University of Medical Sciences, Poznan, Poland.
Zitieren
APA
Osmański, R., Mardas, M., Litwiniuk, M., & Stelmach-Mardas, M. (2026). The prognostic value of selected indices combination in hepatocellular carcinoma patients treated with sorafenib. Reports of Practical Oncology and Radiotherapy, 31(1), 59-67. https://doi.org/10.5603/rpor.111180
Vancouver
Osmański R, Mardas M, Litwiniuk M, Stelmach-Mardas M. The prognostic value of selected indices combination in hepatocellular carcinoma patients treated with sorafenib. Reports of Practical Oncology and Radiotherapy. 2026;31(1):59-67. doi:10.5603/rpor.111180
BibTeX
@article{Osmaski2026,
author = {Osmański, Radosław and Mardas, Marcin and Litwiniuk, Maria and Stelmach-Mardas, Marta},
title = {The prognostic value of selected indices combination in hepatocellular carcinoma patients treated with sorafenib},
journal = {Reports of Practical Oncology and Radiotherapy},
year = {2026},
volume = {31},
number = {1},
pages = {59--67},
doi = {10.5603/rpor.111180}
}
EUVIMED